Comparative in Vitro Surveillance of Amoxicillin-clavulanic Acid and Four Oral Comparators Against 21232 Clinical Isolates from Europe

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2003 Apr 24

PMID 12709842

Citations 2

Authors

D J Hoban

S K Bouchillon

J L Johnson

G G Zhanel

D L Butler

K A Saunders

L A Miller

J A Poupard

Affiliations

Soon will be listed here.

Abstract

The present study was conducted to determine the in vitro activity of amoxicillin-clavulanic acid compared to that of four newer antimicrobial agents (ampicillin, azithromycin, cefuroxime and trimethoprim-sulfamethoxazole). All of the agents were tested against 21232 recent clinical isolates encompassing 37 species submitted from 16 European countries between 1997 and 1999. After 20 years of clinical use, amoxicillin-clavulanic acid continues to retain much of its initial activity against targeted gram-positive organisms, selected gram-negative organisms and major respiratory pathogens.

Citing Articles

New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.

Bulitta J, Landersdorfer C, Kinzig M, Holzgrabe U, Sorgel F Antimicrob Agents Chemother. 2009; 53(8):3462-71.

PMID: 19528278 PMC: 2715586. DOI: 10.1128/AAC.00054-09.

Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.

McCormack P, Keating G Drugs. 2004; 65(1):121-36.

PMID: 15610061 DOI: 10.2165/00003495-200565010-00014.

References

Doern G . Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. J Antimicrob Chemother. 1996; 38 Suppl A:59-69. DOI: 10.1093/jac/38.suppl_a.59. View

Sahm D, Jones M, Hickey M, Diakun D, Mani S, Thornsberry C . Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother. 2000; 45(4):457-66. DOI: 10.1093/jac/45.4.457. View

Oliver A, Perez-Vazquez M, Martinez-Ferrer M, Baquero F, de Rafael L, Canton R . Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes. Antimicrob Agents Chemother. 1999; 43(4):862-7. PMC: 89218. DOI: 10.1128/AAC.43.4.862. View

Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R . Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial.... Clin Infect Dis. 2001; 32 Suppl 2:S114-32. DOI: 10.1086/320184. View

Hunter P, Reeves D . The current status of surveillance of resistance to antimicrobial agents: report on a meeting. J Antimicrob Chemother. 2001; 49(1):17-23. DOI: 10.1093/jac/49.1.17. View

Hoban D, Doern G, Fluit A, Roussel-Delvallez M, Jones R . Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001; 32 Suppl 2:S81-93. DOI: 10.1086/320181. View

Low D, Keller N, Barth A, Jones R . Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001; 32 Suppl 2:S133-45. DOI: 10.1086/320185. View

Bartlett J . Treatment of community-acquired pneumonia. Chemotherapy. 2000; 46 Suppl 1:24-31. DOI: 10.1159/000048489. View

Duckworth G . Clinical implications of antimicrobial resistance: how big is the problem?. Int J Infect Dis. 2002; 6 Suppl 1:S1-7. DOI: 10.1016/s1201-9712(02)90148-7. View

10.

Bax R, Bywater R, Cornaglia G, Goossens H, Hunter P, Isham V . Surveillance of antimicrobial resistance--what, how and whither?. Clin Microbiol Infect. 2001; 7(6):316-25. DOI: 10.1046/j.1198-743x.2001.00239.x. View

11.

Carrie A, Zhanel G . Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance. Drugs. 1999; 57(6):871-81. DOI: 10.2165/00003495-199957060-00004. View

12.

Butler D, Gagnon R, Miller L, Poupard J, Felmingham D, Gruneberg R . Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996. J Antimicrob Chemother. 1999; 43(6):777-82. DOI: 10.1093/jac/43.6.777. View

13.

Ball P, Geddes A, Rolinson G . Amoxycillin clavulanate: an assessment after 15 years of clinical application. J Chemother. 1997; 9(3):167-98. DOI: 10.1179/joc.1997.9.3.167. View